Jaguar8 commented on a stock · Aug 6 15:23

NEWS

Aquestive Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Aquestive Therapeutics (NASDAQ:AQST) reported its Q2 2024 financial results and shared business updates. Key highlights include:

Anaphylm™ (epinephrine) Sublingual Film remains on track for FDA submission in early 2025, with a potential launch by late 2025 or early 2026.

Positive topline pharmacokinetic (PK) and pharmacodynamic (PD) data reported, showing no significant differences based on temperature and pH variability.

Libervant™ (diazepam) Buccal Film expanded for ages two to five, with national retail distribution expected by Q4 2024.

Q2 2024 revenue surged 52% to $20.1 million, up from $13.2 million in Q2 2023.

Net loss decreased to $2.7 million from $5.8 million in Q2 2023, with non-GAAP adjusted EBITDA income at $1.8 million.

Cash reserves stand at approximately $90 million, with a cash runway extending into 2026.

An investor call is scheduled for August 7, 2024, at 8:00 am ET.

Positive
Revenue increased by 52% to $20.1 million in Q2 2024 compared to Q2 2023.

Net loss reduced to $2.7 million from $5.8 million year-over-year.

Non-GAAP adjusted EBITDA income was $1.8 million in Q2 2024.

Positive topline PK and PD data for Anaphylm™.

Cash and cash equivalents at approximately $90 million, with a runway into 2026.

Negative
Manufacture and supply revenue decreased to $8.1 million from $11.6 million year-over-year.

Research and development expenses increased to $4.2 million from $3.5 million year-over-year.

Selling, general, and administrative expenses increased to $11.4 million from $7.4 million year-over-year.

Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more

Translate

Report

4036 Views

Comment

Jaguar8

Spread kindness and love. Life is short. Don’t let greed eat you.

1632Followers

89Following

12KVisitors